Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Noosa News21 hours agoCrystal Beale’s final moments revealed before her body was found in Brisbane River
-
General24 hours agoNauru refugees. Indefinite detention a definite breach of High Court ruling
-
General23 hours agoQueensland teachers to hold statewide rallies but stop short of announcing strike date
-
Noosa News23 hours agoHead of Pedal Group, 99 Bikes reveals what he wrote in e-bikes letter to Queensland Premier